Pharmena S.A. (WSE:PHR)

Poland flag Poland · Delayed Price · Currency is PLN
3.270
+0.020 (0.62%)
Apr 8, 2026, 2:05 PM CET
Market Cap36.20M -29.2%
Revenue (ttm)1.58M +488.4%
Net Income-2.77M
EPS-0.25
Shares Out11.14M
PE Ration/a
Forward PEn/a
Dividend0.85 (26.15%)
Ex-Dividend Daten/a
Volume891
Average Volume2,315
Open3.270
Previous Close3.250
Day's Range3.250 - 3.290
52-Week Range2.500 - 4.490
Beta0.63
RSI43.83
Earnings DateMay 28, 2026

About Pharmena

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 7
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PHR
Full Company Profile

Financial Performance

In 2025, Pharmena's revenue was 1.58 million, an increase of 488.43% compared to the previous year's 268,000. Losses were -2.77 million, 119.4% more than in 2024.

Financial Statements